Back to Search Start Over

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy11Professor Robert Chevalier served as a guest editor for this paper

Authors :
Saulo Klahr
Keith A. Hruska
Theodore C. Simon
Jeremiah J. Morrissey
Song Wang
Frank Strebeck
Helen Liapis
Lala R. Chaudhary
Qing Chen
Source :
Kidney International. 63:2037-2049
Publication Year :
2003
Publisher :
Elsevier BV, 2003.

Abstract

Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy.BackgroundBone morphogenic protein-7 (BMP-7), an essential developmental renal morphogen, is a secreted differentiation factor of the adult collecting duct. It activates receptors in the collecting duct, distal nephron, proximal tubule, and glomerulus. BMP-7 is therapeutic in tubulointerstitial nephritis raising the question of broader efficacy in chronic kidney disease (CKD).MethodsDiabetes was induced in 200g rats by a single dose of streptozotocin. After 16 weeks, glomerular hypertrophy and proteinuria were established, and therapy with BMP-7 (10, 30, or 100 μg/kg intravenously twice a week), enalapril (20 mg/kg), or vehicle was begun and continued until 32 weeks. Kidney weight, glomerular filtration rate (GFR), urine albumin excretion, blood pressure, pathology, and BMP-7 expression were measured.ResultsDiabetic vehicle-treated rats developed renal insufficiency by 32 weeks (GFR, 0.34±0.02 mL/min/100 g body weight vs. 0.55±0.02 in normal). In the diabetic BMP-7 high-dose–treated rats, GFR was preserved (0.70±0.08, P < 0.01 vs. vehicle), and higher than diabetic enalapril-treated rats (0.58±0.06). Kidney weights of vehicle-treated animals were not affected, but were reduced in all of the treatment groups (P < 0.001). Proteinuria was reversed to normal by BMP-7 in a dose-dependent manner. The reduction in proteinuria by the intermediate dose of BMP-7 was similar to the effect of enalapril therapy. Glomerular area and interstitial volume were significantly decreased in the BMP-7 and enalapril-treated animals. Glomerular sclerosis was prevented by BMP-7 therapy more effectively than by enalapril. Enalapril controlled hypertension throughout the course of therapy while BMP-7 did not affect blood pressure until the final 4 weeks of therapy. Diabetic vehicle-treated rats lost BMP-7 expression in the kidney. BMP-7 and enalapril therapy restored BMP-7 expression at high levels.ConclusionBMP-7 partially reversed diabetic-induced kidney hypertrophy, restoring GFR, urine albumin excretion, and glomerular histology toward normal. Restoration of BMP-7 expression was associated with a successful repair reaction and a reversal of the ill-fated injury response.

Details

ISSN :
00852538
Volume :
63
Database :
OpenAIRE
Journal :
Kidney International
Accession number :
edsair.doi.dedup.....1e3c0f3a60ae8cedf738109c39bc8303
Full Text :
https://doi.org/10.1046/j.1523-1755.2003.00035.x